Ocular Therapeutix, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M | $17.4M | $4.2M | $2.0M |
| Cost of Revenue | $6.6M | $5.6M | $5.3M | $4.5M | $4.4M | $2.1M | $2.3M | $465.0K |
| Gross Profit | $45.4M | $58.1M | $53.2M | $47.0M | $39.1M | $15.3M | $1.9M | $1.5M |
| Gross Margin | 87.3% | 91.2% | 91.0% | 91.2% | 89.9% | 88.0% | 45.0% | 76.6% |
| Operating Expenses | ||||||||
| Research & Development | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M | $28.7M | $41.1M | $36.9M |
| SG&A Expense | $64.4M | $60.7M | $33.9M | $32.2M | $31.9M | $22.9M | $22.1M | $18.8M |
| Operating Income | $-270.0M | $-171.8M | $-82.4M | $-78.7M | $-78.0M | $-62.8M | $-85.8M | $-59.1M |
| Operating Margin | -519.8% | -269.6% | -141.0% | -152.7% | -179.3% | -361.1% | -2,029.9% | -2,970.8% |
| Interest Expense | — | $887.0K | $11.3M | $7.0M | $6.7M | $6.8M | $6.1M | $1.7M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-265.9M | $-193.5M | $-80.7M | $-71.0M | $-6.6M | $-155.6M | $-86.4M | $-60.0M |
| Net Margin | -511.9% | -303.7% | -138.1% | -138.0% | -15.1% | -894.3% | -2,043.3% | -3,014.0% |
| EPS (Basic) | $-1.42 | $-1.22 | $-1.01 | $-0.92 | $-0.09 | $-2.56 | $-1.91 | $-1.57 |
| EPS (Diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | $-1.57 |
| Shares Outstanding (Basic) | 187.2M | 158.3M | 79.8M | 76.9M | 76.4M | 60.8M | 45.3M | 41.5M |
| Shares Outstanding (Diluted) | 187.2M | 158.3M | 85.6M | 82.6M | 82.2M | 60.8M | 45.3M | 41.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |